Compare Novartis AG (NVS) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs ProShares UltraPro S&P500 — how do they compare? Novartis AG trades at $152.33 (market cap $295.37B), while ProShares UltraPro S&P500 trades at $154.52. The key difference: Novartis AG pays a 3.07% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | UPRO | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $155.10 |
52-Week Low | $119.31 | $89.29 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $155.10, up 1.72% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The stock faces resistance near $156 and support at $154, while the RSI indicates potential overbought conditions. Recent news highlights S&P 500 strength, with JPMorgan raising its 2026 target to 8,000, driven by AI-driven earnings growth and robust corporate performance.
The outlook remains positive amid strong market momentum, but risks include overvaluation concerns and sensitivity to economic data. Upside potential hinges on sustained earnings growth, while pullbacks may occur if breadth weakens or inflation fears resurface.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
